Current Report · Items 8.01 · 8-K

Relmada Therapeutics, Inc.

RLMDNASDAQEQUITYCurrent

Other Events

Item 8.01 Other Events. Dr. Raj S. Pruthi’s employment as Chief Medical Officer - Urology of Relmada Therapeutics, Inc., ended on September 3, 2026.

Filed Sep 8, 2026Accepted Sep 8, 2026, 8:00 AM EDTCIK 1553643Accession 0001213900-26-097851

View company →Permanent SEC source ↗

Company context

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.

Current securities

RLMDNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

RELMADA THERAPEUTICS, INC. · 8-K · Filed 2026-09-08

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, $0.001 par value per share

Symbol: RLMD
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-09-03

Dimensions: Not supplied

Accession 000121390026097851 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events